Image courtesy of Society of Vascular Surgery
January 5, 2015 — The first large-scale, multispecialty prospective clinical research trial to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment in the United States — initiated by a collaboration between the Society of Interventional Radiology (SIR) and the Society for Vascular Surgery (SVS) — is set to enroll the first patient in spring 2015 with participation from seven filter manufacturers.
Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) will directly address an August 2010 U.S. Food and Drug Administration (FDA) medical alert detailing the possibility that retrievable IVC filters could move or break, potentially causing significant health risks for patients. SVS and SIR collaboratively formed the IVC Filter Study Group Foundation, a 501(c)(3) nonprofit entity that sponsors and oversees PRESERVE. The study will have the goal of obtaining a real worldview of the safety and effectiveness of most filters placed in the United States.
“The PRESERVE study will benefit patients by helping determine how well filters prevent pulmonary embolism and when retrievable filters should be removed,” noted Peter Lawrence, M.D., foundation vice president.
"Patient safety is imperative, which is why interventional radiologists and vascular surgeons are working together collaboratively to respond to FDA's concerns regarding filter safety and effectiveness," said John Kaufman, M.D., FSIR, foundation president.
Filter manufacturers are providing financial support to the IVC Filter Study Group Foundation to sponsor the PRESERVE study. The manufacturers and devices that will be included in the study are ALN Implants Chirurgicaux (ALN Vena Cava Filters); Argon Medical Devices Inc. (Option Elite Retrievable Vena Cava Filter designed and manufactured by Rex Medical); B. Braun Interventional Systems Inc. (VenaTech LP Vena Cava Filter); Bard Peripheral Vascular Inc. (Denali Vena Cava Filter System); Cook Inc. (Cook Günther Tulip Vena Cava Filter); Cordis Corp. (Cordis OptEase Retrievable Vena Cava Filter/Cordis TrapEase Vena Cava Filter) and Volcano Corp. (Crux Vena Cava Filter System).
The five-year study will evaluate the overall safety and efficacy of filters placed by doctors and intends to enroll 2,100 patients at approximately 60 centers in the United States. There will be at least 300 patients enrolled for each participating manufacturer filter, and patients will be evaluated every six months post procedure up to 24 months or filter retrieval. Principal investigators are Matthew Johnson, M.D., FSIR, Indiana University School of Medicine, Indianapolis, Ind. and David Gillespie M.D., FACS, Southcoast Health System, Fall River, Mass.
Protocol development has been completed and an investigational device exemption (IDE) study with HIPAA (Health Insurance Portability and Accountability Act) compliance has been granted by the FDA. Members of the IVC Filter Study Group Foundation have been working with the contract research organization New England Research Institutes Inc. (NERI), and it’s expected that the first patients may enroll in spring 2015.
According to the U.S. Surgeon General, between 350,000 and 600,000 people each year in the United States are affected by blood clots and between 100,000 and 180,000 people die of pulmonary embolism each year. The FDA recommendations are that physicians remove the filters, which are designed to be retrievable, once the threat of pulmonary embolism has passed. The FDA warning said that all physicians were encouraged to consider the benefits and health risks of IVC filter removal for each patient.
Members of the IVC Filter Study Group Foundation board of directors (besides Kaufman and Lawrence) are SVS Executive Director Rebecca Maron, CAE (secretary); SIR Executive Director Susan Sedory Holzer, MA, CAE (treasurer); Peter Gloviczki, M.D., FACS (SVS representative); and Marshall Hicks, M.D., FSIR (SIR representative).
For more information: www.SIRweb.org, www.vascularweb.org